OCALA, Fla. — November 18, 2025 — Leads & Copy — AIM ImmunoTech Inc. (NYSE American: AIM) has released a business update and its financial results for the third quarter of 2025, highlighting clinical and operational progress and key milestones in its drug development programs.
According to AIM Chief Executive Officer Thomas K. Equels, the company’s focus is on advancing Ampligen toward FDA approval as part of a combination therapy for pancreatic cancer. Positive mid-year safety and efficacy data was recently reported in the DURIPANC clinical trial, which combines Ampligen with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer.
A year-end update from the DURIPANC clinical trial is expected by the end of the current quarter.
Other recent highlights include:
- Presentation of data from a completed Phase 2 clinical study of Ampligen in advanced recurrent ovarian cancer at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting by the University of Pittsburgh Medical Center.
- Grant of European Patent No. 4,096,675, for compositions treating Long COVID, covering AIM’s proprietary dsRNAs, including Ampligen, for use in Long COVID treatment.
- Patent secured in Japan through 2039 for a novel cancer therapy that combines Ampligen with checkpoint inhibitors.
- Publication of a peer-reviewed article in the Journal for ImmunoTherapy of Cancer (JITC) showing a positive combination effect of Ampligen and interferon-alpha on tumor growth and subject survival.
- Presentation of progress from Ampligen clinical programs in pancreatic cancer at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care in Warsaw, Poland.
As of September 30, 2025, AIM reported cash, cash equivalents, and marketable investments totaling $2.4 million.
Research and development expenses for the three months ended September 30, 2025, were approximately $607,000, compared to $1.4 million for the same period in 2024.
General and administrative expenses totaled approximately $1.8 million for the three months ended September 30, 2025, compared to $3.1 million for the same period in 2024.
The net loss from operations for the three months ended September 30, 2025, was approximately $(3.3 million), or $(1.57) per share, compared to $(3.7 million), or $(6.00) per share, for the three months ended September 30, 2024. This includes non-recurring expenses. AIM anticipates a monthly burn rate of approximately $550,000, which isolates true operating cash outflows and differs from the net loss due to non-cash items and accounting adjustments.
AIM ImmunoTech Inc. is focused on the research and development of therapeutics for multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The company’s lead product is Ampligen (rintatolimod), an investigational drug and TLR3 agonist immuno-modulator.
On November 17, 2025, AIM filed its September 30, 2025 Form 10-Q after receiving an extension from the SEC. Refer to the full Form 10-Q for complete details.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
Source: AIM ImmunoTech Inc.
